Logotyp Captor Therapeutics

Captor Therapeutics ®

Pipeline

Target
Indications
Modality
Discovery
Preclinical*
IND Filing
Phase IA / IB
  • GSPT1, NEK7, SALL4
    Hepatocellular carcinoma, Lung cancer, NET tumours
    MG
  • NEK7
    Autoimmunity, CNS, Metabolism, Oncology
    MG
  • MCL-1
    Liquid & solid tumours
    BID
  • PKCӨ
    Autoimmunity, Oncology, Transplantation, Metabolism
    BID
  • New target projects
    Autoimmunity, Cancer
    MG BID
  • New E3 ligase degraders
    Autoimmunity, Cancer
    MG BID

*Preclinical stage include IND-enabling studies, 

BID – Bi-functional Degrader; MG – Molecular Glue

Assumed stage at the end of 2025